Cite
HARVARD Citation
Mody, R. et al. (n.d.). Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet oncology. 18 (7), pp. 946-957. [Online].